VIR Vir Biotechnology, Inc. stock chart & analysis
Conviction 10HealthcareScan · Fri, Nov 6, 2026Vir Biotechnology, Inc. (VIR) closed at $12.21 (+10.80%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 60, RS Rating 98, -1.9% from its 52-week high, +102.4% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).
Why VIR moved
From the StockSetups movers recaps that covered VIR, newest first. A recap states what was known that day.
- Premarket+22.9%
Vir is up 22.9% premarket, at $15.00, on 432,487 shares versus a 20-day average of 1,672,485. Market cap is $2.1B, much larger than the others here.
Premarket Movers Nov 9, 2026: Why CKX, GFR, EDSA Are Up →
Financials as of Wed, Sep 30, 2026 · quarterly.
VIR technical analysis
Trend
VIR is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 10.6% above the 50-day ($11.03) and 26.6% above the 200-day ($9.64). ADX(14) at 18 points to a weak trend — more range than direction. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 60, in the bullish half of its range. MACD crossed above its signal line 8 sessions ago. Its RS Rating of 98 puts its weighted 12-month performance ahead of about 98% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 1.0× its 20-day average. It trades about $18.4M a day on average. ATR(14) is $0.7060, 5.8% of price — its typical daily range. Chaikin Money Flow (-0.06) shows distribution.
Key levels
The chart pattern's support is $9.97 and its resistance $12.10. The 52-week range is $4.82 to $12.44; price is 1.9% below the high and 153.5% above the low. The VWAP anchored at the 52-week high is $12.00, below price.
Performance
VIR returned +8.0% (1 week), +9.8% (1 month), +37.3% (3 months), +33.8% (6 months), +126.0% (1 year), +102.4% (year to date).
About Vir Biotechnology, Inc.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Biological Products, (No Diagnostic Substances) · Listed 2019 · 367 employees
Recent news
- Vir Biotechnology Reports Positive Phase 3 Hepatitis Delta Trial ResultsTipRanks · Mon, Nov 9, 2026
- Vir Biotechnology Shares Rise 22% as Phase 3 Hepatitis Delta Trial Meets Primary and Secondary EndpointsAdvfn · Mon, Nov 9, 2026
- Form 8K Vir Biotechnology Inc For: 9 November By Investing.comInvesting.com Canada · Mon, Nov 9, 2026
- Vir Stock Soars After Late-Stage Trial Win. Why Biotech Could Be Headed for the FDAYahoo Finance · Mon, Nov 9, 2026
- Why is Vir Biotechnology stock surging today?Investing.com · Mon, Nov 9, 2026
- Why is Vir Biotechnology stock surging today? By Investing.comInvesting.com UK · Mon, Nov 9, 2026
- Vir Biotechnology stock jumps 22% after hepatitis delta Phase 3 trial successInvesting.com · Mon, Nov 9, 2026
- Vir Biotechnology stock Analysis closes at $12.21, up 10.8%The Cryptonomist · Mon, Nov 9, 2026
- Vir Biotechnology (VIR) Shares Surge 16% on Positive Phase 3 HepGuruFocus · Mon, Nov 9, 2026
- Biggest stock movers Monday: NVDA, VIR, and moreSeeking Alpha · Mon, Nov 9, 2026
Insider activity
SEC Form 4 transactions in VIR · open-market 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
de Verneuil Vanina EVP, General Counsel, Corp Sec · Common Stock · 2026-11-03 | Sell | 2.41K | $27K | 2026-11-03 | 2026-11-04 |
de Verneuil Vanina EVP, General Counsel, Corp Sec · Common Stock · 2026-11-02 | Sell | 1.34K | $15K | 2026-11-02 | 2026-11-04 |
Topalian Suzanne Louise Director · Common Stock · 2026-10-27 | Grant | 8K | — | 2026-10-27 | 2026-10-28 |
Topalian Suzanne Louise Director · Common Stock · 2026-10-27 | Grant | 4.73K | — | 2026-10-27 | 2026-10-28 |
Topalian Suzanne Louise Director · Stock Option (Right to Buy) · 2026-10-27 | Grant | 9.46K | — | 2026-10-27 | 2026-10-28 |
Topalian Suzanne Louise Director · Stock Option (Right to Buy) · 2026-10-27 | Grant | 16K | — | 2026-10-27 | 2026-10-28 |
MORE ROBERT J Director · Common Stock · 2026-08-11 | Dispose | 8K | — | 2026-08-11 | 2026-08-12 |
MORE ROBERT J Director · Common Stock · 2026-08-11 | Acquire | 8K | — | 2026-08-11 | 2026-08-12 |
Coughlin Timothy Director · Stock Option (Right to Buy) · 2026-06-09 | Grant | 16K | $0 | 2026-06-09 | 2026-06-10 |
Coughlin Timothy Director · Common Stock · 2026-06-09 | Grant | 8K | $0 | 2026-06-09 | 2026-06-10 |
SEC filings
EDGAR filings in VIR · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.